MedTrace Logo

[S,S]-Reboxetine Add-On Trial

NCT00334685 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2019-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with \[S,S\]-Reboxetine against pregabalin monotherapy in patients with PHN

Conditions

Interventions

DRUG

[S,S]-Reboxetine + Pregabalin

\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks

DRUG

Pregabalin

Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-22
Primary Completion
2007-10-04
Completion
2007-10-11

Countries

  • United States
  • Austria
  • Canada
  • Czechia
  • Germany
  • Italy
  • Latvia
  • Netherlands
  • Norway
  • Poland
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334685 on ClinicalTrials.gov